Physician profile
Daniel R Rhoads
NPI 1316046162
$9,245.17
in general payments reported to CMS, 2019-2025
28 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,272 · 2022: $1,535 · 2023: $2,134 · 2024: $3,000 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981 · Consulting Fee: $1,063 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.50 |
| Consulting Fee | $1,062.50 |
| Education | $394.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,191.77 | 2021-2025 | |
| Janssen Biotech, INC. | $2,143.64 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $862.78 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $841.60 | 2021-2025 | Olumiant, Taltz, Zepbound |
| Pfizer INC. | $374.76 | 2021-2025 | |
| Amgen INC. | $374.75 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $372.17 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $364.29 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $335.45 | 2021-2024 | Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $214.93 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.18 | 2021-2023 | Targretin, Siliq |
| Novartis Pharmaceuticals Corporation | $180.09 | 2021-2025 | |
| Incyte Corporation | $132.42 | 2021-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.06 | 2022-2024 | Spevigo, Cyltezo |
| Biofrontera INC. | $115.23 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $66.89 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $50.73 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $45.55 | 2023-2024 | Tremfya |
| Genzyme Corporation | $42.05 | 2021-2023 | |
| Organogenesis INC. | $38.29 | 2023-2024 | Puraply |
| Merz North America, INC. | $31.30 | 2021 | |
| Blueprint Medicines Corporation | $27.29 | 2025 | Ayvakit |
| Organon LLC | $25.77 | 2025 | Hadlima |
| Stemline Therapeutics INC. | $23.79 | 2022 | |
| Krystal Biotech INC | $22.61 | 2023 | Vyjuvek |
| Genentech USA, INC. | $19.87 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $14.73 | 2023 | Xtrac |
| Allergan, INC. | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rhoads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.